Nurix Therapeutics

Founded 2009 · Biotech · Private

E3 ligase-based platform for targeted protein degradation in cancer

Claim this profile

Follows are private to you and power your alerts

Updated · nurixtx.com

Sector
Biotech
Founded
2009
Latest Form D
$120M, Mar 2020
Total capital
$142M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$142M
5 Form D · last Mar 2020
79 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
18
22 pending · first 2022
Rank in peer group#94 of 1449

Capital timeline

20122014201620182020FEDERAL ↑EQUITY ↓Cumulative $142M1st Form D$3.1M3rd Form D$2.1M4th Form D$17M5th Form D$120M
20122014201620182020FEDERAL ↑EQUITY ↓Cumulative $142M4th Form D$17M5th Form D$120M

Latest events

  • Private capital raisedForm D · SEC · 5th filing$120M
  • Private capital raisedForm D · SEC · 4th filing$17M
  • Private capital raisedForm D · SEC · 3rd filing$2.1M
  • Private capital raisedForm D · SEC · 2nd filing$2K
  • Private capital raisedForm D · SEC · 1st filing$3.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#94 · top 6%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Arthur SandsResearcherExecutive Officer, DirectorLinked by 1 patent
  • Christine RingExecutive OfficerNamed in SEC Form D filings
  • David LaceyDirectorNamed in SEC Form D filings
  • Hans van HouteExecutive OfficerNamed in SEC Form D filings
  • Jeff TongDirectorNamed in SEC Form D filings
  • Julia GregoryDirectorNamed in SEC Form D filings
Show all 9 people
  • Leon ChenDirectorNamed in SEC Form D filings
  • Lori KunkelDirectorNamed in SEC Form D filings
  • Robert TjianDirectorNamed in SEC Form D filings

What it has protected

USPTO · 18 granted of 40
Show all 40 patent records
  • AERIE PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
  • Gate BioscienceSimilar federal contract value in Biotech · null in contracts
  • InsitroSimilar federal contract value in Biotech · null in contracts
  • FIVE ELEVEN PHARMA, INC.Similar federal contract value in Biotech · null in contracts
  • Z BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
  • Antios Therapeutics Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .